New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareGonadorelin vs Eloralintide

Gonadorelin vs Eloralintide

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & LibidoAnti-Aging & Longevity
Gonadorelin
GLP-1 / Weight Loss Agonists
Eloralintide
Summary
Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Half-Life
~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
~7 days (estimated, long-acting design)
Admin Route
SubQ, Intranasal
SubQ
Research
Typical Dose
100 mcg
Under investigation in Phase 1/2 trials
Frequency
Twice daily (every 12 hours)
Once weekly
Key Benefits
  • Maintains testicular size during TRT
  • Preserves fertility and sperm production during testosterone use
  • Stimulates endogenous LH/FSH production
  • Maintains HPG axis function during exogenous hormone use
  • Used for HCG-free TRT protocols
  • Helps restart natural testosterone production (PCT)
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
Side Effects
  • Injection site reactions
  • Headache
  • Nausea at initiation
  • Tachycardia (rare)
  • +1 more
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
Stacks With